Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Acta Neurol Scand ; 130(2): 97-102, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24720783

RESUMEN

BACKGROUND: To minimize the risk of progressive multifocal leucoencephalopathy (PML), treatment with natalizumab is often stopped after 2 years, but evidence upon rebound of disease activity is limited and controversial. OBJECTIVE: To evaluate effects of natalizumab discontinuation on clinical disease activity within twelve months after cessation. METHODS: We retrospectively analyzed data of 201 patients with MS who discontinued natalizumab between 2007 and 2012. Mean change scores of annualized relapse rate (ARR) and expanded disability status scale (EDSS) were calculated for detection of rebound disease activity after twelve months. RESULTS: Natalizumab exposure did not exceed 2 years in 50.2% of patients, and the most common reasons for discontinuation were a long treatment period and concern of PML (56%). A total of 11.9% experienced a rebound phenomenon within twelve months. Mean ARR prenatalizumab was lower (P = 0.001, 95% CI -1.0-0.000) and treatment response to natalizumab poorer (P < 0.001, 95% CI 0.4-1.3) in patients with rebound compared to those without, but rebound was not associated with brief exposure to natalizumab (P = 0.159, 95% CI -9.3-1.5). 86.1% of patients switched to another therapy. Patients without rebound were found more often in the group starting an alternative treatment early (P = 0.013). CONCLUSION: Our data suggest that rebound of MS disease activity affects a subgroup of patients (11.9%), especially those with low disease activity before natalizumab therapy and a longer treatment gap after its withdrawal.


Asunto(s)
Anticuerpos Monoclonales Humanizados/administración & dosificación , Síndrome de Abstinencia a Sustancias/etiología , Adulto , Femenino , Humanos , Masculino , Esclerosis Múltiple/tratamiento farmacológico , Natalizumab , Estudios Retrospectivos
2.
Z Rheumatol ; 72(7): 714-6, 718, 2013 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-23685853

RESUMEN

Isolated monarthritis caused by Tropheryma whipplei without involvement of the gastrointestinal tract is rare but is nowadays often described as an early manifestation of the disease. In a male patient with recurrent knee joint arthritis for several years, we could ultimately diagnose Whipple's disease based on PCR positive biopsies of synovial tissue and fluid. Furthermore, the patient was found to be an asymptomatic T. whipplei carrier. With adequate antibiotic therapy the patient has meanwhile fully recovered.


Asunto(s)
Antibacterianos/uso terapéutico , Artritis/tratamiento farmacológico , Artritis/microbiología , Tropheryma , Enfermedad de Whipple/tratamiento farmacológico , Enfermedad de Whipple/microbiología , Artritis/diagnóstico , Diagnóstico Diferencial , Humanos , Articulación de la Rodilla , Masculino , Persona de Mediana Edad , Enfermedades Raras/diagnóstico , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/microbiología , Resultado del Tratamiento , Enfermedad de Whipple/diagnóstico
3.
Unfallchirurg ; 115(11): 1034-7, 2012 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-21909735

RESUMEN

Combined forearm fractures are identified according to their location as Galeazzi, Monteggia or Essex-Lopresti injuries. The feature common to these three forms is the combination of a forearm fracture with instability of the distal or proximal radio-ulnar joint. The combination of Galeazzi and Monteggia fractures in the same extremity is an exceedingly rare occurrence. It has been reported in eight cases including two pediatric patients worldwide. In this case report the rare occurrence of the combination of these injuries and the possibility of pitfalls in the operative treatment are presented.


Asunto(s)
Traumatismos del Antebrazo/diagnóstico por imagen , Traumatismos del Antebrazo/cirugía , Fijación Interna de Fracturas/instrumentación , Fracturas del Radio/diagnóstico por imagen , Fracturas del Radio/cirugía , Fracturas del Cúbito/diagnóstico por imagen , Fracturas del Cúbito/cirugía , Adulto , Fijación Interna de Fracturas/métodos , Humanos , Masculino , Radiografía , Resultado del Tratamiento
4.
J Clin Invest ; 105(7): 967-76, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10749576

RESUMEN

We examined the effect of glatiramer acetate, a random copolymer of alanine, lysine, glutamic acid, and tyrosine, on antigen-specific T-cell responses in patients with multiple sclerosis (MS). Glatiramer acetate (Copaxone) functioned as a universal antigen, inducing proliferation, independent of any prior exposure to the polymer, in T-cell lines prepared from MS or healthy subjects. However, for most patients, daily injections of glatiramer acetate abolished this T-cell response and promoted the secretion of IL-5 and IL-13, which are characteristic of Th2 cells. The surviving glatiramer acetate-reactive T cells exhibited a greater degree of degeneracy as measured by cross-reactive responses to combinatorial peptide libraries. Thus, it appears that, in some individuals, in vivo administration of glatiramer acetate induces highly cross-reactive T cells that secrete Th2 cytokines. To our knowledge, glatiramer acetate is the first agent that suppresses human autoimmune disease and alters immune function by engaging the T-cell receptor. This compound may be useful in a variety of autoimmune disorders in which immune deviation to a Th2 type of response is desirable.


Asunto(s)
Inmunosupresores/farmacología , Esclerosis Múltiple/inmunología , Péptidos/farmacología , Células Th2/efectos de los fármacos , Adulto , Secuencia de Aminoácidos , División Celular , Células Cultivadas , Reacciones Cruzadas , Epítopos de Linfocito T/inmunología , Femenino , Acetato de Glatiramer , Humanos , Epítopos Inmunodominantes/inmunología , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Interferón gamma/metabolismo , Interleucina-5/metabolismo , Leucocitos Mononucleares/citología , Ligandos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Esclerosis Múltiple/tratamiento farmacológico , Proteína Básica de Mielina/inmunología , Vaina de Mielina/inmunología , Fragmentos de Péptidos/inmunología , Péptidos/administración & dosificación , Péptidos/uso terapéutico , Toxoide Tetánico/inmunología , Células Th2/inmunología
5.
J Neuropathol Exp Neurol ; 55(12): 1205-9, 1996 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8957443

RESUMEN

Apoptosis plays a crucial role in natural recovery from T cell-mediated autoimmune disorders of the nervous system. Whether apoptosis also occurs in human inflammatory myopathies is unclear. In this study we examined muscle biopsy specimens from untreated patients with polymyositis (n = 12), dermatomyositis (n = 12), and inclusion body myositis (n = 12) for the presence of apoptosis using morphological criteria and DNA fragmentation by in situ tailing. In all these disorders, only rare T cells exhibited signs of apoptosis by nuclear morphology and in situ labeling techniques. Although Fas-expression was upregulated in a few inflammatory cells, increased apoptosis of the surrounding T cells was not observed. Further, nuclei of degenerating muscle fibers did not show morphological signs of apoptosis and were not labeled by the tailing reaction. We conclude that in the inflammatory myopathies, T cell inflammation is not cleared by apoptosis and affected muscle fibers do not die by apoptosis. The observations are consistent with the non-self-limited nature of these disorders and suggest that, in contrast to the nervous system, the local microenvironment in muscle does not deliver pro-apoptotic stimuli.


Asunto(s)
Apoptosis/inmunología , Enfermedades Autoinmunes/inmunología , Dermatomiositis/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Fibras Musculares Esqueléticas/inmunología , Miositis por Cuerpos de Inclusión/inmunología , Polimiositis/inmunología , Subgrupos de Linfocitos T/inmunología , Adulto , Anciano , Enfermedades Autoinmunes/patología , Dermatomiositis/patología , Humanos , Hibridación in Situ , Persona de Mediana Edad , Miositis por Cuerpos de Inclusión/patología , Polimiositis/patología , Receptor fas/análisis
6.
J Histochem Cytochem ; 41(7): 1023-30, 1993 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8515045

RESUMEN

Since DNA fragmentation is a key feature of programmed cell death (PCD) and also occurs in certain stages of necrosis, we have adapted the methodology of in situ nick-translation (ISNT) to detect DNA fragmentation on a single-cell level. We first established the technique for cell preparations. Apoptosis was induced by gamma-irradiation on freshly isolated rat thymocytes. After fixation procedures, ISNT was performed by overnight incubation either with fluorescein-12-dUTP or with digoxigenin-labeled 11-dUTP and DNA polymerase I. The enzymatic incorporation of labeled nucleotides at sites of DNA fragmentation was detected by flow cytometry either directly or indirectly with fluorescein-conjugated anti-digoxigenin. The quantitative results demonstrated close correlation with morphological essays for apoptosis, DNA gel electrophoresis, and ISNT. Proliferating cells determined by bromodeoxyuridine immunofluorescence were not labeled by ISNT. Immunocytochemistry for cell surface antigens in combination with ISNT allowed the identification of specific cell types undergoing PCD. Furthermore, the simultaneous application of photolabeling techniques with ethidium monoazide and ISNT led to the identification of DNA fragmentation in cells with still intact membranes. Extending ISNT to tissue sections of paraformaldehyde-fixed, paraffin-embedded material reliably revealed labeling of cells with typical morphological features of apoptosis. However, this technique was not useful in detecting early stages of necrotic cell death.


Asunto(s)
Apoptosis , Daño del ADN , Técnicas Genéticas , Animales , Azidas , División Celular , Células Cultivadas , Nucleótidos de Desoxiuracil , Digoxigenina/análogos & derivados , Encefalomielitis Autoinmune Experimental/patología , Citometría de Flujo , Fluoresceínas , Inmunohistoquímica , Técnicas In Vitro , Masculino , Ratas , Ratas Endogámicas Lew , Ratas Sprague-Dawley , Timo/citología , Timo/metabolismo , Timo/efectos de la radiación
7.
Scanning ; 24(2): 92-100, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-11998907

RESUMEN

Automated analysis of submicron particles by computer-controlled scanning electron microscopy is generally possible. The minimum diameter of the detectable particles is dependent on the mean atomic number of the particles and the operating parameters of the scanning microscope. The main limitation with regard to particle size is set by the quality of the particle detection system, which generally is the backscatter electron detector. The accuracy of the results of the x-ray analyses is very often strongly affected by specimen damage, omnipresent especially for environmental particles even at low electron energies and probe currents. With the exception for light elements, the detection limit is approximately 1 wt%. Device-related limitations to automated analysis may be specimen drift and an unreliable autofocus function.

8.
Wien Klin Wochenschr ; 106(11): 335-44, 1994.
Artículo en Alemán | MEDLINE | ID: mdl-8053201

RESUMEN

The highly potent neurotoxins produced by Clostridium botulinum lead to botulism when ingested in appreciable amounts. However, botulinum toxin injections delivered intramuscularly in very small quantities can produce a therapeutically intended focal paresis while producing only negligible local or systemic side effects. Over the past several years, various neurological disorders, especially those involving increased muscle tone and/or abnormal movements, have been successfully treated with local botulinum A toxin injections. The success of this method has led to a general change in the management of blepharospasm, torticollis spasmodicus, hemifacial spasm, and other disorders. Treatment is usually effective for 4 to 12 weeks; if symptoms recur, the injections can be repeated over a period of several years, usually with the same success. Side effects depend on the site of the injections, and are rare at the optimal dosage and always reversible. For optimum therapeutic results, this treatment must be restricted to specialized centers.


Asunto(s)
Toxinas Botulínicas/administración & dosificación , Enfermedades Neuromusculares/rehabilitación , Toxinas Botulínicas/efectos adversos , Esquema de Medicación , Humanos , Inyecciones Intramusculares , Examen Neurológico/efectos de los fármacos , Enfermedades Neuromusculares/etiología
9.
Neurology ; 67(11): 2029-31, 2006 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-17159113

RESUMEN

We sequenced 61 patients with various idiopathic generalized epilepsy (IGE) syndromes for mutations in the EFHC1 gene. We detected three novel heterozygous missense mutations (I174V, C259Y, A394S) and one possibly pathogenic variant in the 3' UTR (2014t>c). The mutation I174V was also detected in 1 of 372 screened patients with temporal lobe epilepsy. We conclude that mutations in the EFHC1 gene may underlie different types of epilepsy syndromes.


Asunto(s)
Proteínas de Unión al Calcio/genética , Epilepsia Generalizada/genética , Fenotipo , Regiones no Traducidas 3'/genética , Adulto , Femenino , Variación Genética , Humanos , Masculino , Mutación Missense , Síndrome
10.
Neurogenetics ; 7(4): 265-8, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16932951

RESUMEN

Mutations in the chloride channel gene CLCN2 have been reported in families with generalized and focal epilepsy syndromes. To evaluate the contribution of mutations in the CLCN2 gene to the etiology of epilepsies in our population, we screened 96 patients with different epilepsy syndromes and a putative genetic background. No definite mutations were found in our study population. We conclude that mutations in the CLCN2 gene are only a rare cause of idiopathic generalized epilepsy.


Asunto(s)
Canales de Cloruro/genética , Epilepsia Generalizada/genética , Mutación Puntual , Canales de Cloruro CLC-2 , Pruebas Genéticas , Variación Genética , Humanos
11.
Wien Med Wochenschr ; 146(19-20): 514-9, 1996.
Artículo en Alemán | MEDLINE | ID: mdl-9082651

RESUMEN

There is no cure for multiple sclerosis (MS). Many therapeutic strategies are known. With exception of high dose corticosteroids for the treatment of acute exacerbations most of the concepts are not generally accepted. Reasons are the variable, often unpredictable natural course of MS, the incomplete understanding of the pathophysiology and the difficult trial design. Yet, new therapeutic agents give hope at least to slow the course of the disease.


Asunto(s)
Esclerosis Múltiple/terapia , Azatioprina/administración & dosificación , Cladribina/administración & dosificación , Ciclofosfamida/administración & dosificación , Acetato de Glatiramer , Humanos , Interferón beta/administración & dosificación , Metotrexato/administración & dosificación , Mitoxantrona/administración & dosificación , Péptidos/administración & dosificación , Plasmaféresis , Ensayos Clínicos Controlados Aleatorios como Asunto
12.
Glia ; 7(1): 19-24, 1993 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-7678581

RESUMEN

Infection of the central nervous (CNS) system by the human immunodeficiency virus (HIV) depends on the migration of infected hematogenous cells into the brain. We thus used quantitative light and electron microscopic immunocytochemistry to study the homing and turnover of bone marrow derived cells in the CNS in radiation bone marrow chimeras under normal conditions and in experimental autoimmune encephalomyelitis (EAE) as an experimental model of brain inflammation. Our studies suggest the following conclusions. First, the central nervous system is continuously patrolled by a small number of T-lymphocytes and monocytes. Meningeal and perivascular monocytes are slowly replaced by hematogenous cells under normal conditions, and this turnover is accelerated in the course of inflammation. In contrast, resident microglia represent a very stable cell pool, which in adult animals is only exceptionally replaced by hematogenous cells, even after recovery from severe brain inflammation. Second, although in bone-marrow-chimeric animals resident microglia, astrocytes, and ependymal cells are not able to present antigen to Lewis T-lymphocytes, the inflammatory reaction in EAE is qualitatively and quantitatively similar in these animals compared to fully histocompatible Lewis rats. Finally, resident microglia express the macrophage activation antigen ED1. Thus, microglia cells appear to function as effector cells in EAE lesions.


Asunto(s)
Médula Ósea/patología , Encefalitis/patología , Neuroglía/patología , Animales , Enfermedades Autoinmunes/inmunología , Médula Ósea/efectos de la radiación , Quimera , Encefalomielitis Autoinmune Experimental/inmunología , Antígenos de Histocompatibilidad/inmunología , Inmunohistoquímica , Meninges/patología , Microscopía Electrónica , Proteína Básica de Mielina/inmunología , Ratas , Ratas Endogámicas Lew
13.
Am J Pathol ; 143(2): 446-52, 1993 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8342595

RESUMEN

In experimental autoimmune encephalomyelitis (EAE) myelin-specific T lymphocytes attack the myelinated tissue of the central nervous system (CNS). In the Lewis rat, EAE as a rule has an acute, monophasic course. With spontaneous clinical recovery the inflammatory CNS infiltrates are cleared from the nervous tissue within a few days. This is well in line with the remarkably low incidence of myelin-specific T cells present in EAE infiltrate. Combining immunocytochemical techniques, ultrastructural criteria and in situ nick translation we found up to 49% of T lymphocytes in EAE lesions showing signs of apoptosis at the time of recovery from disease. Our results suggest that apoptosis of T lymphocytes may be one possible mechanism to eliminate T lymphocytes from inflammatory brain lesions.


Asunto(s)
Apoptosis , Encéfalo/ultraestructura , Encefalomielitis Autoinmune Experimental/patología , Linfocitos T/ultraestructura , Animales , Muerte Celular , Daño del ADN , Encefalomielitis Autoinmune Experimental/fisiopatología , Técnicas Genéticas , Técnicas para Inmunoenzimas , Recuento de Leucocitos , Ratas , Ratas Endogámicas Lew , Ratas Sprague-Dawley
14.
J Immunol ; 165(12): 7300-7, 2000 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-11120865

RESUMEN

The capacity of glatiramer acetate (GA), a random copolymer of alanine, lysine, glutamic acid, and tyrosine to stimulate primary in vitro human and murine T cell proliferation was examined. PBMCs isolated from healthy humans and relapsing remitting multiple sclerosis patients and spleen cells from inbred strains of mice, expressing different H-2 haplotypes, were used as sources of non-GA-primed lymphocytes. GA functioned as a universal Ag, inducing dose-dependent proliferation of all non-GA-primed human and murine T cell populations tested. Moreover, GA stimulated PBMCs derived ex vivo from human cord blood, strongly suggesting that GA can activate both naive and memory T cells. The human T cell proliferative responses to GA were HLA class II DR-restricted by virtue of the ability of anti-class II Ab to inhibit T cell proliferation, and the demonstration that individual GA specific human T cell clones were HLA class II DR-restricted by either restriction element but not both. Furthermore, GA-reactive T cells secreted Th0 cytokines and expressed a diverse repertoire of TCR. Limiting dilution analysis indicated that the T cell precursor frequency among the healthy human adults tested ranged from 1:5,000 to 1:125,000. Given that all of the T cell populations tested were isolated from non-GA-primed donors, it appears that virtually all humans and murine strains contain significant numbers of T cell populations cross-reactive with GA. These findings may explain the recent clinical finding that daily s.c. administration of GA ameliorates the progression of multiple sclerosis.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Activación de Linfocitos , Péptidos/inmunología , Péptidos/metabolismo , Adulto , Animales , Linfocitos T CD4-Positivos/citología , Línea Celular Transformada , Separación Celular , Células Clonales , Relación Dosis-Respuesta Inmunológica , Femenino , Acetato de Glatiramer , Antígenos HLA-DR/genética , Antígenos HLA-DR/metabolismo , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/inmunología , Humanos , Inmunización , Memoria Inmunológica/genética , Separación Inmunomagnética , Recién Nacido , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/inmunología , Activación de Linfocitos/genética , Recuento de Linfocitos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Esclerosis Múltiple Recurrente-Remitente/inmunología , Péptidos/síntesis química , Péptidos/farmacología , Bazo/citología , Bazo/inmunología , Células TH1/citología , Células TH1/inmunología , Células TH1/metabolismo , Células Th2/citología , Células Th2/inmunología , Células Th2/metabolismo
15.
Clin Immunol ; 106(3): 163-74, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12706402

RESUMEN

Glatiramer acetate (GA; Copaxone) is a random sequence polypeptide used in the treatment of relapsing remitting multiple sclerosis (RR MS). We have recently demonstrated that prior to treatment, GA induces proliferation of resting T cells and is not cross-reactive with myelin antigens. Daily GA injections induce a significant loss of this GA responsiveness, which is associated with the induction of highly cross-reactive Th2-type T cells potentially capable of suppressing inflammatory responses. The mechanism of action by which GA induces T cell nonresponsiveness leading to T cell receptor degeneracy in patients with RR MS is unknown. Here, we examined the effects of daily GA administration on the induction of T cell hyporesponsiveness. The frequency of GA-reactive T cells in peripheral blood of seven patients with RR MS was measured by limiting dilution analysis prior to and during 6 months of treatment. In addition, a model in which GA-reactive T cells were stimulated in vitro was developed to better characterize the selection of T cell populations over time. In vivo treatment with GA induced a decrease in GA-reactive T cell frequencies and hyporesponsiveness of CD4(+) T cell reactivity to GA in vitro that was only partially reversed by the addition of IL-2. These data suggest that T cell peripheral tolerance to GA was achieved in vivo during treatment. Thus, our in vitro data suggest that the underlying changes in GA-reactive CD4(+) T cell reactivity could be explained by the induction of T cell anergy and clonal elimination.


Asunto(s)
Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Péptidos/farmacología , Linfocitos T/efectos de los fármacos , Adulto , Presentación de Antígeno/efectos de los fármacos , Citocinas/biosíntesis , Relación Dosis-Respuesta a Droga , Femenino , Acetato de Glatiramer , Humanos , Tolerancia Inmunológica/efectos de los fármacos , Inyecciones Subcutáneas , Interleucina-2/farmacología , Masculino , Esclerosis Múltiple Recurrente-Remitente/inmunología , Péptidos/administración & dosificación , Proteínas Recombinantes/farmacología , Linfocitos T/inmunología
16.
Nervenarzt ; 66(6): 465-7, 1995 Jun.
Artículo en Alemán | MEDLINE | ID: mdl-7637833

RESUMEN

After major head trauma, a 28-year-old male patient developed tetraparesis with marked left-sided contractions of the leg adductors. Spasticity was resistant to antispastic drugs and intensive physiotherapy. Therefore, we injected 12.5 ng botulinum A toxin (Dysport) in the left adductor longus and adductor magnus. Eight measurements of the post-micturition residual urine of the bladder before botulinum-A-toxin administration gave no evidence for urinary retention. Between day 5 and 14 after injection we measured pathologically increased urinary volumes up to 130 ml at five different points of time. This case report indicates possible subclinical side effects on the autonomic nervous system of the urinary bladder.


Asunto(s)
Toxinas Botulínicas/efectos adversos , Traumatismos Cerrados de la Cabeza/rehabilitación , Espasticidad Muscular/rehabilitación , Cuadriplejía/rehabilitación , Retención Urinaria/inducido químicamente , Urodinámica/efectos de los fármacos , Adulto , Sistema Nervioso Autónomo/efectos de los fármacos , Toxinas Botulínicas/administración & dosificación , Terapia Combinada , Humanos , Inyecciones Intramusculares , Masculino , Modalidades de Fisioterapia , Vejiga Urinaria/inervación , Retención Urinaria/diagnóstico
17.
Psychiatr Prax ; 24(5): 227-30, 1997 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-9417544

RESUMEN

The psychiatric services of the Swiss region of Basel-Landschaft observed an increasing deterioration and shortage of accommodation offers for mentally ill persons. At the same time, it grew temporarily more and more difficult to let single rooms in flat-sharing communities. Therefore a psychiatric services research project aimed at evaluating the wishes and needs of specialists in the housing sphere, and of about 600 in- and outpatients, as well as for their caregivers. The results showed, similar to other studies, on the one hand patients' predominant wish to live independently, whereas on the other hand there was a great difference between the views of patients and their caregivers. The latter view this aspiration for independence rather skeptically. The striking disagreement between patients and caregivers may be fruitful for the therapeutic process; however, this applies only if both partners are aware of this fact.


Asunto(s)
Servicios Comunitarios de Salud Mental/provisión & distribución , Vivienda/estadística & datos numéricos , Trastornos Mentales/rehabilitación , Actividades Cotidianas , Adulto , Anciano , Estudios Transversales , Desinstitucionalización/estadística & datos numéricos , Femenino , Humanos , Incidencia , Masculino , Trastornos Mentales/epidemiología , Persona de Mediana Edad , Satisfacción del Paciente , Calidad de Vida , Deseabilidad Social , Suiza/epidemiología
18.
J Autoimmun ; 9(2): 167-74, 1996 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8738960

RESUMEN

The adrenocortical response is central to recovery from experimental allergic encephalomyelitis (EAE) in the Lewis rat, as reflected by the increased severity of the disease in adrenalectomized animals. The protection conferred by glucocorticoids is related to the immunosuppressive effects of the steroid, which may include apoptosis of immunocompetent cells. Here we describe T-cell infiltration and apoptosis in spinal cord lesions of intact (INT) and adrenalectomized (ADX) rats during the course of EAE. The normal disease course (peak clinical score 3) was induced following intra-peritoneal transfer of 4 x 10(7) myelin basic protein (MBP)-sensitized spleen lymphocytes to INT rats. Maximum apoptosis of infiltrating T cells (32%) was evident on day 7 and was associated with the expected increase in circulating corticosterone levels and the onset of disease remission. ADX rats, which have no corticosterone response, administered 4 x 10(7) cells displayed rapid and fatal EAE with only minimal signs of T-cell apoptosis (1.9-3.8%). In order to delay the onset and prolong the disease in ADX rats, a lower cell dose was used. In ADX rats injected with 1 x 10(6) cells, disease onset was comparable to INT 4 x 10(7) rats but disease progression was equally rapid and T-cell apoptosis (1.4-8.5%) was similarly low to that seen in ADX rats given the higher dose of cells. Transfer of the lower number of splenocytes (1 x 10(6) cells) to INT rats resulted in only mild EAE (clinical score 0.5-1) which was reflected both in low T cell apoptosis (1.7-16%) and circulating corticosterone levels. In all treatment groups very few apoptotic macrophages were detected ( < 1% of all macrophages) and no differences between groups were apparent. The results suggest that glucocorticoid-mediated T-cell apoptosis, whether initiated directly or indirectly, may contribute to the recovery phase of EAE in Lewis rats.


Asunto(s)
Apoptosis , Sistema Nervioso Central/inmunología , Encefalomielitis Autoinmune Experimental/inmunología , Macrófagos/inmunología , Linfocitos T/inmunología , Adrenalectomía , Animales , Apoptosis/efectos de los fármacos , Recuento de Células , Sistema Nervioso Central/patología , Corticosterona/farmacología , Modelos Animales de Enfermedad , Femenino , Cobayas , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , Proteína Básica de Mielina/farmacología , Ratas , Ratas Endogámicas Lew
19.
Acta Neurol Scand ; 100(1): 69-73, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10416515

RESUMEN

OBJECTIVE: To investigate the effects of vaccinations and steroids on disease progression and mood in patients with multiple sclerosis (MS). MATERIAL AND METHODS: Twenty-three patients with clinically definite MS were questioned with respect to vaccination history and the cumulative dose of steroids given during their life-time. EDSS scores and MRI scans of the brain were obtained and used to quantify clinical and MRI disease progression. Mood was assessed by using a self-estimated adjective mood scale. RESULTS: The number of vaccinations showed no effect on disease progression or mood. High cumulative steroid doses were associated with rapid MRI disease progression and the number of supratentorial MRI lesions. The absence of band-like MRI lesions was correlated with rapid clinical and MRI disease progression. Self-estimated mood tended to be worse in patients with chronic-progressive MS compared to those with relapsing-remitting MS. CONCLUSION: Neither clinical nor MRI-documented disease progression nor mood are influenced by the total number of vaccinations whereas high cumulative steroid doses and the absence of band-like MRI lesions indicate rapidly progressive MS. Self-estimated mood tends to be worse in patients with chronic-progressive MS compared to patients with relapsing-remitting MS.


Asunto(s)
Afecto , Inmunoterapia/estadística & datos numéricos , Esclerosis Múltiple/diagnóstico , Esteroides/administración & dosificación , Adulto , Progresión de la Enfermedad , Femenino , Humanos , Esquemas de Inmunización , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios
20.
J Cell Sci ; 104 ( Pt 2): 317-26, 1993 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8389375

RESUMEN

A current hypothesis holds that chromatin fragmentation into oligonucleosomal patterns is an early event during apoptosis. In contrast, induction of apoptosis in cultured hepatocytes by TGF-beta 1 was not associated with DNA fragmentation into oligonucleosomes in hepatocyte monolayers and apoptotic fragments. For a more rigorous test of the hypothesis we performed a number of experiments. We compared nuclear changes resulting from TGF-beta 1 with those induced by Ca2+, a known activator of endonuclease. The morphology of apoptotic and Ca(2+)-treated nuclei was different as judged by DNA staining with Hoechst 33258. Likewise, electron microscopy of apoptotic nuclei showed characteristic condensation of the chromatin as well as dissolution of the nucleolar structure and nuclear fragmentation, changes not seen after Ca2+ treatment, after three hours of incubation. Analysis of DNA fluorescence of nuclei by FACS revealed that treatment with Ca2+ reduced the signal by 20%. In contrast, nuclei from TGF-beta 1-treated hepatocytes did not exhibit a reduced signal and after sorting by FACS, apoptotic nuclei remained in the 2N and 4N fractions. The absence of detectable DNA fragmentation in apoptotic nuclei was further verified by in situ nick translation, not only in hepatocytes but also in a mouse lymphoma cell line. From these findings we conclude that activation of an endonuclease is not an early event on the pathway to morphologically recognizable apoptosis.


Asunto(s)
Apoptosis , Núcleo Celular/efectos de los fármacos , Cromatina/química , Endonucleasas/metabolismo , Membrana Nuclear/química , Animales , Calcio/farmacología , Núcleo Celular/ultraestructura , Células Cultivadas/efectos de los fármacos , Células Cultivadas/ultraestructura , Cromatina/ultraestructura , Activación Enzimática/efectos de los fármacos , Citometría de Flujo , Humanos , Hígado/citología , Ratones , Membrana Nuclear/ultraestructura , Factor de Crecimiento Transformador beta/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA